ClinVar Miner

Submissions for variant NM_138694.4(PKHD1):c.10036T>C (p.Cys3346Arg) (rs149798764)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000587211 SCV000231850 uncertain significance not provided 2018-06-11 criteria provided, single submitter clinical testing
Invitae RCV000195797 SCV000255207 uncertain significance Autosomal recessive polycystic kidney disease 2015-02-25 criteria provided, single submitter clinical testing This sequence change replaces cysteine with arginine at codon 3346 of the PKHD1 protein (p.Cys3346Arg). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and arginine. This variant has been reported in the literature and is present in population databases (rs149798764, 0.07%). This variant has been reported in an individual with autosomal recessive polycystic kidney disease. It has also been reported to co-occur with a homozygous variant an additional gene in an individual with Meckel-Gruber syndrome. (PMID: 12846734, 21493627). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, this is a rare missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance.
Integrated Genetics/Laboratory Corporation of America RCV000587211 SCV000699840 uncertain significance not provided 2017-05-08 criteria provided, single submitter clinical testing Variant summary: The PKHD1 c.10036T>C (p.Cys3346Arg) variant causes a missense change involving the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 41/121406 control chromosomes at a frequency of 0.0003377, which does not exceed the estimated maximal expected allele frequency of a pathogenic PKHD1 variant (0.0070711). This variant was reported in ARPKD patients in compound heterozygosity with other presumably pathogenic/likely pathogenic variants in multiple studies (ROSSETTI_Kidney Int_2003, Tavira_gene_2015, and Eisenberger_PlosONE_2014). One study reported this variant to co-occur with a homozygous variant an additional gene in an individual with Meckel-Gruber syndrome. (Hopp_2011), however, the zygosity of this variant was not mentioned therefore, the possibility of incidental heterozysity for this variant cannot be ruled out and this evidence has not been weighted in this classification.in Multiple clinical diagnostic laboratories via ClinVar have classified this variant as uncertain significance without evidence for independent evaluation. However, a locus specific database (http://www.humgen.rwth-aachen.de) reports this variant as "Pathogenic". Taken together, this variant is classified as VUS-possibly pathogenic, until more clinical and functional data becomes available.
Counsyl RCV000195797 SCV000793823 uncertain significance Autosomal recessive polycystic kidney disease 2017-11-14 criteria provided, single submitter clinical testing
SIB Swiss Institute of Bioinformatics RCV000195797 SCV000803504 uncertain significance Autosomal recessive polycystic kidney disease 2018-05-31 criteria provided, single submitter curation This variant is interpreted as a Uncertain Significance - Conflicting Evidence, for Polycystic kidney disease 4 with or without polycystic liver disease, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:12846734). BS2 => Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Department of Genetics,Sultan Qaboos University Hospital, Oman RCV000195797 SCV000891698 pathogenic Autosomal recessive polycystic kidney disease 2017-12-30 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000195797 SCV000897288 uncertain significance Autosomal recessive polycystic kidney disease 2018-10-31 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000195797 SCV000915169 uncertain significance Autosomal recessive polycystic kidney disease 2018-12-21 criteria provided, single submitter clinical testing The PKHD1 c.10036T>C (p.Cys3346Arg) variant is a missense variant that has been reported in a compound heterozygous state in two unrelated individuals with polycystic kidney disease (Rosetti et al. 2003; Tatvira et al. 2015). It has also been reported in a heterozygous state in two individuals with polycystic kidney in whom an alternative molecular diagnosis was identified (Hopp et al. 2011; Eisenberger et al. 2015). The p.Cys3346Arg variant was absent from 50 control individuals but is reported at a frequency of 0.001061 in the Ashkenazi Jewish population of the Genome Aggregation Database. Notably, the variant is reported in a homozygous state in one individual in this population. However, disease severity is variable, and rare cases of adult onset have been reported. Functional studies of this variant have not been conducted. Based on the available evidence, the p.Cys3346Arg variant is classified as of uncertain significance but suspicious for pathogenicity for polycystic kidney disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.